Predictive value of neutrophil-lymphocyte ratio for prognosis in patients with advanced hepatocellular carcinoma treated with programmed cell death 1 inhibitors

Table 2 Comparison of hematological parameters between patients with good prognosis and poor prognosis, mean ± SD

Variable	Good prognosis group (n = 126)	Poor prognosis group (n = 108)	t	P value
AFP (ng/mL)	585.42 ± 146.85	762.18 ± 176.41	8.248	< 0.001
NLR	2.85 ± 0.72	3.82 ± 1.02	8.296	< 0.001
ALT (U/L)	45.86 ± 10.48	48.17 ± 11.27	1.626	0.105
AST (U/L)	50.24 ± 12.31	54.39 ± 13.76	2.438	0.016
Total bilirubin (μmol/L)	18.86 ± 4.28	20.62 ± 4.92	2.943	0.004
Albumin (g/L)	38.42 ± 3.81	36.87 ± 3.94	3.046	0.003
International normalized ratio	1.11 ± 0.26	1.22 ± 0.27	2.928	0.004
Blood urea nitrogen (mmol/L)	5.27 ± 1.12	5.48 ± 1.26	1.345	0.180
Serum creatinine (μmol/L)	78.46 ± 15.23	81.34 ± 16.48	1.385	0.167

AFP: Alpha fetoprotein; NLR: Neutrophil-to-lymphocyte ratio; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase.